Confo Therapeutics – Stabilize. Target. Discover. Transform.
Transform. Confo Therapeutics’ unparalleled technology stabilizes functional conformations of GPCRs (G protein-coupled receptors) to uncover a wide range of previously inaccessible drug targets.
About us - Confo Therapeutics
Empowered by our unrivalled Confo® technology and a world-class team of experts in GPCRs, structural biology, computer-aided drug design and medicinal chemistry, we aim to become leaders in the discovery and development of impactful GPCR-modulating medicines.
Pipeline - Confo Therapeutics
Confo Therapeutics is building a pipeline of drug candidates with the potential to transform therapeutic outcomes for patients with severe illnesses lacking disease-modifying treatments. G protein-coupled receptors (GPCRs) are the largest and most diverse group of membrane receptors in the body.
Confo Therapeutics Announces Publication in Nature …
Oct 1, 2024 · Discovery of highly potent and selective antibody-based GPCR agonists targeting Melanocortin 4 Receptor (MC4R), a key regulator for hunger and satiety, using Confo’s proprietary technology...
Confo Therapeutics Announces Global Licensing Agreement with …
Mar 2, 2023 · Confo Therapeutics, a leader in the discovery of medicines targeting G-protein coupled receptors (GPCRs), today announced a worldwide licensing agreem.
Confo Therapeutics - LinkedIn
Confo Therapeutics’ unparalleled technology stabilizes functional conformations of GPCRs (G protein-coupled receptors) to uncover a wide range of previously inaccessible GPCRs as drug targets.
Confo Therapeutics Enters into Research Collaboration for GPCR ...
Jun 15, 2023 · Confo Therapeutics’ unparalleled technology stabilizes functional conformations of GPCRs (G-protein coupled receptors), thereby enabling the discovery of chemical or biological ligands...
Confo Therapeutics Enters Collaborative Agreement with Regeneron
Nov 30, 2021 · Confo Therapeutics’ unparalleled technology stabilizes functional conformations of GPCRs (G protein-coupled receptors) to uncover a wide range of previously inaccessible drug targets.
Lilly inks deal with Confo for GPCR drug candidate
Mar 12, 2023 · Eli Lilly and Company and Confo Therapeutics, a developer of drugs that target G-protein-coupled receptors (GCPRs), have signed a worldwide licensing agreement for Confo compound CFTX-1554 and back-up compounds.
Confo Therapeutics Announces Global Licensing Agreement with …
Ghent, Belgium – March 2, 2023 – Confo Therapeutics, a leader in the discovery of medicines targeting G-protein coupled receptors (GPCRs), today announced a worldwide licensing agreement with Eli Lilly and Company for Confo’s clinical stage CFTX-1554 and …